Key facts
- Vesica Health’s last known valuation is $31.0M (Mar 2026).
- It has raised $4.5M across 1 recorded rounds; the latest was Seed Round ($4.5M) in Mar 2026.
- 1 investment vehicle was formed to buy Vesica Health shares in the last 12 months, reporting $420K sold to 10 investors, per SEC Form D filings.
- Vesica Health has filed 1 Form D with the SEC, most recently Mar 2026 ($4.5M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Vesica Health
Funding rounds
1 roundsSecondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Vesica Health shares, reporting $420K sold to 10 investors. Most recent filing Feb 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Vesica Health
Developer of diagnostic technology designed for clinical evaluation of patients with hematuria and early detection of bladder cancer. The company's platform applies a noninvasive urine-based test that integrates multi-omic analysis of DNA biomarkers, including methylation and somatic mutation profiles, alongside clinical risk factors to stratify patients by cancer likelihood, enabling healthcare providers to identify high-risk individuals for timely referral, reduce unnecessary invasive procedures, improve diagnostic accuracy, support patient management, and enhance outcomes in bladder cancer care.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2022
- Employees
- 5
- Website
- vesicahealth.com/
- Ownership
- Privately Held (backing)
Vesica Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vesica Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vesica Health in its N-PORT filings yet. We sweep new filings monthly.